Bio-Rad Laboratories, Inc. BIO recently entered into a binding agreement to purchase all equity interests in Stilla Technologies ("Stilla"). Stilla’s next-generation digital PCR solutions complement ...

HERCULES, Calif. - Bio-Rad Laboratories, Inc. (NYSE:BIO) reported fourth-quarter results that fell short of analyst ...

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company has entered into a binding offer to ...

Reports Q4 revenue $667.5M, consensus $679.75M. Norman Schwartz, Bio-Rad’s (BIO) Chairman and CEO, commented: “Bio-Rad demonstrated ...

Full Year 2024 Results Key Financial Results Revenue: US$2.57b (down 3.9% from ...

StockNews.com lowered shares of Bio-Rad Laboratories (NYSE:BIO – Free Report) from a buy rating to a hold rating in a research note issued to investors on Monday morning. Other analysts have also ...

(RTTNews) - OncoCyte Corp. (OCX), a diagnostics technology ... to close around February 10. Bio-Rad will provide additional financial support for an upcoming clinical trial and commercialization ...

Highlights,Bio-Rad Laboratories (BIO) drives innovation in life sciences and clinical diagnostics with a diversified product ...

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through ...

Bio-Rad Laboratories ... It operates through the Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory ...